Multiple prospective trials and publications in PSMA ligand imaging and therapy in Prostate cancer since 2014.

Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade. Emmett L, Joshua A, Epstein R, Ho B,  Nguyen Q,  Cusick T,Hickey A, Hruby G, Kneebone A, Chalasani V, O’Neill G, Stricker P. SNMMI oral presentation June 2018.

Results of a prospective trial of  Lu¹⁷⁷ DKFZ 617 PSMA  therapy for metastatic castrate resistant prostate cancer : Imaging predictors of treatment response and patterns of progression. Louise Emmett^1,2,3, Megan Crumbaker, Bao Ho, Kathy Willowson, Peter Eu, Lalith Ratnayake, Richard Epstein, Ashley Blanksby, Lisa Horvath, Alex Guminski, Kate Mahon, Charlotte Yin, Phillip Stricker, Anthony M. Joshua. (currently in submission Eur Urol Oncol July 2018. Presented WFNMB April 2018)

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017).J Med Radiat Sci, 64(1), 52-60.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. van Leeuwen, P. J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q., & Stricker, P. D. (2017). BJU Int, 119(2), 209-215. doi:10.1111/bju.1354

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976.

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., & Woo, H. H. (2017). Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2017.23

Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Hruby, G., Eade, T., Kneebone, A., Emmett, L., Guo, L., Ho, B., . . . Kwong, C. (2017). Radiother Oncol, 122(1), 99-102.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., . . . Emmett, L. (2015). J Nucl Med, 56(8), 1185-1190.

Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., . . . Emmett, L. (2016). (68) BJU Int, 117(5), 732-739. doi:10.1111/bju.13397

Initial multicentre experience of 68 Gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. Siriwardana, A., Thompson, J., van Leeuwen, P. J., Doig, S., Kalsbeek, A., Emmett, L., . . . Stricker, P. (2017). BJU Int. doi:10.1111/bju.13919

Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., . . . Chiti, A. (2017). Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-017-3725-1

Fendler, W. P., Calais, J., Allen-Auerbach, M., Bluemel, C., Eberhardt, N., Emmett, L., . . . Eiber, M. (2017). 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. doi:10.2967/jnumed.117.190827

Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP.AJR Am J Roentgenol. 2018 Jun 27:1-9

Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.

Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.

Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET.

Byrne K, Eade T, Kneebone A, Guo L, Hsiao E, Schembri G, Kwong C, Hunter J, Emmett L, Hruby G.

Radiother Oncol. 2018 Feb;126(2):244-248. doi: 10.1016/j.radonc.2017.10.022. Epub 2017 Nov 10.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.

J Nucl Med. 2018 Jan;59(1):82-88